FDA Recalls Generic Zyrtec Tablets Over Possible Ranitidine Contamination
Unique Pharmaceutical Laboratories voluntarily recalled its generic cetirizine hydrochloride 5 mg tablets on July 18, 2026, over possible ranitidine cross-contamination, the FDA said.[1]
The recall covers 100-tablet bottles in four lots — GY825029, GY825030, GY825031 and GY825032 — all expiring in October 2028 and distributed nationwide by Rising Pharma Holdings Inc.[1] The FDA warns people who are hypersensitive to ranitidine ingredients could suffer severe, potentially life-threatening reactions, though no adverse events have been reported to date.[1]
Unique Pharmaceutical Laboratories announced the voluntary recall because of the possible ranitidine cross-contamination in its cetirizine product, and the FDA posted the notice to alert consumers and health professionals.[1]
Show source details & analysis (1 source)
📌 Key Facts
- On July 18, 2026, Unique Pharmaceutical Laboratories voluntarily recalled cetirizine hydrochloride tablets USP 5 mg due to possible ranitidine cross-contamination.
- The recall affects 100-tablet bottles in four lots (GY825029, GY825030, GY825031, GY825032) expiring in October 2028, distributed nationwide by Rising Pharma Holdings Inc.
- The FDA says consumers hypersensitive to ranitidine ingredients could suffer severe, potentially life-threatening reactions, though no adverse events have been reported to date.
📰 Source Timeline (1)
Follow how coverage of this story developed over time